

HOLD

Price (14/10/2020)	EUR 122.35
Target price	115.00
Risk	High
Reuters	GLPG AS
Bloomberg	GLPG NA
Shares number (m)	65.25
Market cap. (m)	7,984
Cash Position 12/18 (m)	1,291
1 year price perf.	-13.8%
Diff. with Euro Stoxx	-9.0%
Volume (sh./day)	548,886
Free Float	49.2%
H/L 1 year	249.50 - 102.45

Galapagos
ROCELLA Phase 2b failed meeting its primary endpoint

- The company today announced the failure of the ROCELLA Ph2b trial
- Today's news has an impact on valuation

Facts:

- The ROCELLA trial is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of ADAMTS-5 inhibitor GLPG1972 in 932 patients with knee osteoarthritis (OA) over 52 weeks of treatment.
- The primary objective of the trial was to demonstrate a significant reduction in cartilage loss versus placebo. The trial failed to meet this objective. The change from baseline to week 52 in cartilage thickness, in mm (SD) was -0.116 (0.27) for the placebo group and -0.068 (0.20), -0.097 (0.27) and -0.085 (0.22), for the low, medium and high dose, respectively. Statistically significant difference versus placebo was not reached in any of the treated groups.
- There was also no significant difference compared to placebo observed on secondary endpoints, including clinical outcomes.
- GLPG1972 was generally well-tolerated by patients.

Our View:

- Today's announcement is an unfortunate setback, given the high unmet need and substantial market opportunity for novel, disease-modifying drug candidates in OA.
- Prior to today's news, we attributed a 26% success rate to the GLPG1972 program and projected potential peak sales of EUR 2bn. This contributed EUR 292m or EUR 5 per share to our SOTP.

Investment conclusion:

We cut our TP from EUR 120 per share to EUR 115 per share following the exclusion of the GLPG1972 program from our SOTP. We value Galapagos using an rNPV model (WACC: 12%; **Exhibit 1**). The main contributors are the strong cash position and the filgotinib programs. With relatively light newsflow expected near-term, we recommend Holding the stock and await US regulatory feedback on filgotinib and readouts of more advanced programs, such as the Phase 3 of ziritaxestat in idiopathic pulmonary fibrosis (IPF), expected in 2022.

EUR	12/16	12/17	12/18	12/19	12/20e	12/21e	12/22e
Revenues	151.6	155.9	317.8	895.9	496.6	911.2	669.9
R & D	140	219	323	427	556	667	767
EBIT	-11.5	-89.8	-44.8	370.3	-218.8	15.2	-403.8
Decl. profit	54.0	-116	-29.3	150	-272	-2.6	-418
EPS	1.17	-2.27	-0.57	2.49	-4.18	-0.04	-6.41
EV/Revenues	12.1	18.4	8.9	6.1	5.9	3.7	6.4
EV/R & D	13.2	13.1	8.8	12.7	5.3	5.1	5.6
P/E	52.2	nm	nm	74.9	nm	nm	nm
Net Cash	980	1,151	1,291	5,775	5,062	4,593	3,706


Analyst:
Benoit Louage, PhD

+32 2 662 89 55

b.louage@degroofpetercam.com

Exhibit 1

Drug	Indication	Stage	Success rate	Launch	Peak sales (EUR m)	rNPV (EUR m)	rNPV/share (EUR)	% of SOTP
Filgotinib	RA	NDA	90% (US) - 100% (EU/JP)	2020 (EU/JP) - 2022 (US)	1,836	2,266	35	30%
Filgotinib	UC	PhIII	50%	2021	284	153	2	2%
Filgotinib	CD	PhIII	57%	2022	403	218	3	3%
Filgotinib	PsA	PhIII	57%	2023	350	132	2	2%
Filgotinib	AS	PhII	57%	2023	232	68	1	1%
Filgotinib total					3,105	2,836	43	38%
ziritaxestat+GLPG1205	IPF	PhIII	42%	2023	1,682	856	13	11%
ziritaxestat	SSc	PhII	21%	2024	715	73	1	1%
Net cash						5,566	85	74%
Overhead						-1,798	-28	-24%
Valuation						7,533	115	100%

Source: Degroof Petercam estimates

Degroof Petercam Financial Markets

www.degroofpetercam.com

Nijverheidsstraat / Rue de l'Industrie 44 – 1040 Brussels

De Entrée 238 A 7th floor – 1101 EE Amsterdam

Benoît Mortelmans +32 2 662 82 93

Equity Research / Analysts

Fernand de Boer	Retail/Food & Beverages	+31 20 573 5417
Kris Kippers	Consumer Goods/Holdings	+32 2 287 9259
Frank Claassen	Industrials	+31 20 573 5409
Thomas Guillot, PharmD	Biotech/Healthcare	+32 2 287 8906
Benoit Louage, PhD	Biotech/Healthcare	+32 2 662 8955
Vivien Maquet	Telecom/Utilities/Real Estate	+32 2 662 8446
Inna Maslova	Real Estate	+32 2 662 8644
Michael Roeg	Technology	+31 20 573 5422
Luuk van Beek	Energy/Engineering/Construction	+31 20 573 5471
Herman van der Loos, CFA	Real Estate	+32 2 662 8304

Sales

Anthony della Faille	+32 2 662 8724
Laurent Pierret	+32 2 662 8654

Equity Sales

Simon Vlamincx	+32 2 662 8291
Damien Fontaine	+32 2 662 8287
Assia Adanouj	+32 2 662 8768
Emma Boucherie	+32 2 662 8834
Victor van Eijk	+31 20 573 5436
Beatrice Leysens - Assistant	+32 2 662 8262

Miet Coppens	Support & Editing	+32 2 287 9582
Christel De Clerck	Support & Editing	+32 2 662 8302
Monique Gérard	Support & Editing	+32 2 662 8301

Sales Trading

Veronique De Schoemaeker	+32 2 662 8280
Pascal Burm	+32 2 662 8283
Frédéric Lebrun	+32 2 287 9190

Corporate Brokerage & Syndication

Gert Potvlieghe		+32 2 662 8289
Raymond de Wolff		+31 20 573 5414
Tineke Hosselaer	Corporate access	+32 2 662 8290
Charlotte Mertens	Corporate access	+31 20 573 5416

Fixed Income Sales

Peter Oscé	+32 2 287 9862
Sandra Timmermans	+32 2 662 8852
Olivier Gigognon	+32 2 287 9184

Derivatives

Karim Marrakchi	+32 2 662 8940
Eric Debeaud	+32 2 287 98 27
Thierry De Wispelaere	+32 2 662 8674

Applicable disclosures

- Degroof Petercam acts as a liquidity provider for this company and is paid for these services.
- Degroof Petercam has provided corporate finance services in the past 12 months for this company.

Investment rating system: The Degroof Petercam stock ratings are based on the estimated performance relative to the Degroof Petercam Benelux coverage universe. The total return required for a given rating depends on the risk profile relative to this universe. This risk profile is represented by the Beta, as estimated by the analyst. Low risk stocks have an estimated Beta below or equal to 0.9, Medium risk stocks have a Beta between 0.9 and 1.3 and High risk stocks have a Beta equal to or above 1.3. The required relative performance for a given rating is indicated below. The price targets given and the expected relative performance are always based on a 12 month time horizon.

	SELL	REDUCE	HOLD	ADD	BUY
High Beta >= 1.3	RP < -15%	-15% <= RP < -6%	-6% <= RP < +6%	+6% <= RP < +15%	RP >= 15%
Medium 0.9 < Beta > 1.3	RP < -10%	-10% <= RP < -4%	-4% <= RP < +4%	+4% <= RP < +10%	RP >= 10%
Low Beta <= 0.9	RP < -6%	-6% <= RP < -2%	-2% <= RP < +2%	+2% <= RP < +6%	RP >= 6%

RP : Relative Performance against Degroof Petercam coverage universe

Information about rating distribution can be found [here](#).

Additional company related disclosures, including any potential conflicts of interest, recommendation history and analyst remuneration can be found at (password protected): <https://research.degroofpetercam.com/>

This document was prepared by Bank Degroof Petercam, S.A. ("BDP"), a company authorized in Belgium to engage in securities activities, under regulatory supervision of the Belgian Financial Services and Markets Authority ("FSMA"). Although the information contained in this report has been obtained from sources considered to be reliable, BDP guarantees neither its accuracy nor its completeness. The Managing Director of BDP Institutional Research & Sales bears final responsibility of this report. This document may not be reproduced in whole or in part or communicated in any other way without BDP's written consent.

Neither this report, nor any information or opinion contained herein, constitutes investment advice, or a solicitation or offer by BDP or its affiliates to buy or sell any security or other financial instrument, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase, or sale would be unlawful under the securities laws of such jurisdiction. BDP may make markets or specialize in, have positions in and effect transactions in securities of companies mentioned and may also perform or seek to perform investment banking services for those companies.

The analyst(s) claim(s) not to have any meaningful financial interest in one of the above mentioned companies nor to have any conflict of interest.

In connection with its dissemination outside the United States, this document is intended for the benefit of institutional and professional investors and is sent for information only. BDP is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended, and may not be provided or redistributed to any other person without the express permission of BDP. BDP has entered into an agreement pursuant to Rule 15a-6 with Global Alliance Securities, LLC ("Global Alliance") a broker-dealer registered with the U.S. Securities and Exchange Commission with offices at 2464 Darts Cove Way Charleston, South Carolina 29466, and member of the Financial Industry Regulatory Authority ("FINRA") member (web: www.globalalliancesecurities.com). Any U.S. recipient of this research report wishing to effect a transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so through Global Alliance. The analyst whose name appears in this research report is not registered or qualified as a research analyst with the FINRA and is not an associated person of Global Alliance and, therefore, may not be subject to applicable restrictions under FINRA rules on communications with a subject company, public appearances, and trading securities held by a research analyst account.

This email and any attachment are confidential. They may contain privileged information and are exclusively intended for the named addressee (s) only. If you are not authorised, you are notified that no part of this page or any attachment may be disclosed, copied or distributed, and that any other action related to this page or attachment is strictly prohibited, and may be unlawful. The Degroof Petercam group shall not be liable for the incorrect or incomplete transmission of this page nor responsible for any delay in receipt. The Degroof Petercam group accepts no liability for any damage resulting from the use and/ or acceptance of the content of this page. The Degroof Petercam group reserves the right to monitor all page access through our network.